Business Description
Hepion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4268974015
Total Employee Number:
2Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 48.2 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 88.6 | |||||
3-Year EPS without NRI Growth Rate | 91.1 | |||||
3-Year FCF Growth Rate | 90.9 | |||||
3-Year Book Growth Rate | -94.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.67 | |||||
9-Day RSI | 40.43 | |||||
14-Day RSI | 43.32 | |||||
3-1 Month Momentum % | 8.56 | |||||
6-1 Month Momentum % | 95.53 | |||||
12-1 Month Momentum % | 61.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.68 | |||||
Quick Ratio | 3.68 | |||||
Cash Ratio | 3.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -434.7 | |||||
Shareholder Yield % | 79.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -96 | |||||
ROA % | -73.35 | |||||
ROIC % | -299.49 | |||||
3-Year ROIIC % | -729.92 | |||||
ROC (Joel Greenblatt) % | -656.16 | |||||
ROCE % | -223.25 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.59 | |||||
Price-to-Tangible-Book | 4.59 | |||||
EV-to-EBIT | -0.16 | |||||
EV-to-EBITDA | -0.16 | |||||
EV-to-FCF | -0.8 | |||||
| Price-to-Net-Current-Asset-Value | 4.59 | |||||
| Price-to-Net-Cash | 0.31 | |||||
Earnings Yield (Greenblatt) % | -625 | |||||
FCF Yield % | -117.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HEPA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hepion Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.2 | ||
| Beta | 1.527 | ||
| 3-Year Sharpe Ratio | -1.3 | ||
| 3-Year Sortino Ratio | -1.42 | ||
| Volatility % | 104.28 | ||
| 14-Day RSI | 43.32 | ||
| 14-Day ATR ($) | 0.011985 | ||
| 20-Day SMA ($) | 0.05846 | ||
| 12-1 Month Momentum % | 61.55 | ||
| 52-Week Range ($) | 0.033 - 0.11 | ||
| Shares Outstanding (Mil) | 29.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hepion Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hepion Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 102 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 12 days | ||
| First quarter earnings results for 2026 | 2026-05-19 | 0.09 (-11.60%) | ||
| General meeting for 2025 | 2026-04-30 | 0.05 (-23.80%) | ||
| Annual report for 2025 | 2026-03-12 | 0.05 (-18.18%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 0.07 (-22.50%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.07 (-16.28%) | ||
| First quarter earnings results for 2025 | 2025-05-19 | 0.11 (-10.33%) | ||
| Annual report for 2024 | 2025-04-08 | 0.44 (-2.87%) | ||
| 0.02:1 Stock Split | 2025-03-18 | 1.04 (-6.73%) |
Show
Entries
Hepion Pharmaceuticals Inc Frequently Asked Questions
What is Hepion Pharmaceuticals Inc(HEPA)'s stock price today?
The current price of HEPA is $0.05. The 52 week high of HEPA is $0.11 and 52 week low is $0.03.
When is next earnings date of Hepion Pharmaceuticals Inc(HEPA)?
The next earnings date of Hepion Pharmaceuticals Inc(HEPA) is 2026-08-14 Est..
Does Hepion Pharmaceuticals Inc(HEPA) pay dividends? If so, how much?
Hepion Pharmaceuticals Inc(HEPA) does not pay dividend.
Guru Commentaries on OTCPK:HEPA
No articles.
Press Release
Articles on Hepion Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers